Clinical trial

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

NCT04177290

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-04-02

PhasePHASE1

Study timeline

Study start (actual)2020-04-02Date precision: day

Registry last updated2023-02-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced or Metastatic NSCLCunresolved

Interventions

Sintilimab (M1b)DRUG

Sintilimab (approved)DRUG

Sponsors & collaborators

Innovent Biologics (Suzhou) Co. Ltd.lead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04177290 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.